Revenue - Schedule of Deferred Revenue (Details) - License and collaboration revenue - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2026
Contract with Customer, Asset (Liability) [Roll Forward]
Beginning balance		$ (56.3)
Additions related to development cost reimbursement received		(20.0)
Additions due to milestone achieved related to FDA approval		(100.0)
Revenue recognized		187.7
Ending balance	$ 11.4	11.4
Exact Science License Agreement
Contract with Customer, Asset (Liability) [Roll Forward]
Revenue recognized	$ 182.5	187.7
Contract asset		$ 11.4